Kyrexa

Kyrexa is a Scottish veterinary oncology company developing Rimcazole, an oral small-molecule cancer therapy that combines direct anti-tumour, anti-angiogenic and immune-engaging activity and is positioned as the first oral immunotherapy for canine cancer. Co-founded in 2023 by veterinary oncologist Dr Clare Knottenbelt and physician-scientist Barbara Spruce, the company has reported tumour responses in pilot studies across 30 dogs with advanced cancers while maintaining patient quality of life. It holds two FDA MUMS designations for canine oral melanoma and squamous cell carcinoma and is targeting US FDA conditional approval by 2030.

  • Seed
  • Biotechnology
  • Healthtech
  • Veterinary Services
  • Healthcare & Life Sciences

1

Round

1

Industry

4

Tags

Nov 4, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Nov 4, 2026

    Seed

    • Animal Health Angels

    Article coming soon.

Pricing

Research Kyrexa — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if Kyrexa is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

© 2026 VeilStrat. All rights reserved.All systems operational